Uric acid and xanthine oxidase: Perspectives in chronic heart failure

Archives of Medical Science

Volumn 4, Issue 3, 2008, Pages 219-225

  Patel, Pawan D ^a   Arora, Rohit R ^a  

^a Chicago Medical School   (United States)

Author keywords

Heart failure; Uric acid; Xanthine oxidase

Indexed keywords

ALLOPURINOL; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIPURINOL; PLACEBO; PROBENECID; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; URIC ACID; XANTHINE OXIDASE;

ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DISEASE MARKER; ENZYME ACTIVITY; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERURICEMIA; LIPID PEROXIDATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PATHOPHYSIOLOGY; PERIPHERAL ISCHEMIA; PROTEIN EXPRESSION; REVIEW; URIC ACID BLOOD LEVEL; VASODILATATION;

EID: 58549096142     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Rosamond W, Flegal K, Furie K, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25-146.
2. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999; 131: 7-13.
3. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-10.
4. Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87: 229-34.
5. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J 1999; 13: 682-5.
6. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997; 18: 858-65.
7. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004; 555: 589-606.
8. Becker BF. Towards the physiological function of uric acid. Free Radic Biol Med 1993; 14: 615-31.
9. Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med 2002; 33: 774-97.
10. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation 2002; 9: 161-75.
11. Keaney JF Jr, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis 1995; 38: 129-54.
12. Godber BL, Doel JJ, Durgan J, Eisenthal R, Harrison R. A new route to peroxynitrite: a role for xanthine oxidoreductase. FEBS Lett 2000; 475: 93-6.
13. Friedl HP, Till GO, Ryan US, Warda PA. Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J 1989; 3: 2512-8.
14. Terada LS, Beehler CJ, Banerjee A, et al. Hyperoxia and self- or neutrophil-generated O2 metabolites inactivate xanthine oxidase. J Appl Physiol 1988; 65: 2349-53.
15. Terada LS, Leff JA, Guidot DM, Willingham IR, Repine JE. Inactivation of xanthine oxidase by hydrogen peroxide involves site-directed hydroxyl radical formation. Free Radic Biol Med 1991; 10: 61-8.
16. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol 1992; 34: 78-84.
17. Watanabe S, Kang D, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-60.
18. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides antioxidant defense in humans against oxidantand radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci 1981; 78: 6858-62.
19. Capasso G, Jaeger P, Robertson WG, Unwin RJ. Uric acid and the kidney: urate transport, stone disease and progressive renal failure. Curr Pharm Des 2005; 11: 4153-9.
20. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998; 19: 1814-22.
21. Jankowska EA, Ponikowska B, Majda J, et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 2007; 115: 151-5.
22. Doehner W, Rauchhaus M, Florea V, et al. Uric acid in cachectic and non-cachectic CHF patients-relation to leg vascular resistance. Am Heart J 2001; 141: 792-9.
23. Cicoira M, Zanolla L, Rossi A, et al. Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 2002; 143: 1107-11.
24. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 2007; 9: 518-24.
25. White CR, Darley-Usmar V, Berrington WR, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci U S A 1996; 93: 8745-9.
26. Saavedra WF, Paolocci N, St John ME, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90: 297-304.
27. Landmesser U, Spiekermann S, Dikalov S, et al. Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation 2002; 106: 3073-8.
28. Hink HU, Santanam N, Dikalov S, et al. Peroxidase properties of extracellular superoxide dismutase: role of uric acid in modulating in vivo activity. Arterioscler Thromb Vasc Biol 2002; 22: 1402-8.
29. Waring WS, Adwani SH, Breukels O, Webb DJ, Maxwell SR. Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart 2004; 90: 155-9.
30. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing plateletderived growth factor A-chain expression. J Biol Chem 1991; 266: 8604-8.
31. Ginsberg M, Henson P, Henson J, Kozin F. Mechanisms of platelet response to monosodium urate crystals. Am J Pathol 1979; 94: 549-68.
32. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-82.
33. Ekelund UE, Harrison RW, Shokek O, et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacinginduced heart failure. Circ Res 1999; 85: 437-45.
34. Hassoun PM, Yu FS, Shedd AL, et al. Regulation of endothelial cell xanthine dehydrogenase/oxidase gene expression by oxygen tension. Am J Physiol 1994; 266: L163-71.
35. Saugstad OD. Role of xanthine oxidase and its inhibitor in hypoxia: reoxygenation injury. Pediatrics 1996; 98: 103-7.
36. Ochiai ME, Barretto AC, Oliveira MT Jr, Munhoz RT, Morgado PC, Ramires JA. Uric acid renal excretion and renal insufficiency in decompensated severe heart failure. Eur J Heart Fail 2005; 7: 468-74.
37. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 1997; 30: 527-32.
38. Leyva F, Anker SD, Egerer K, Stevenson JC, Kox WJ, Coats AJ. Hyperleptinaemia in chronic heart failure. Relationships with insulin. Eur Heart J 1998; 19: 1547-51.
39. Alexander MC, Lomanto M, Nasrin N, Ramaika C. Insulin stimulates glyceraldehyde- 3-phosphate dehydrogenase gene expression through cis-acting DNA sequences. Proc Natl Acad Sci 1988; 85: 5092-6.
40. Liedtke AJ, Hugues HC, Neely JR. Effects of excess glucose and insulin on glycolytic metabolism during experimental myocardial ischemia. Am J Cardiol 1976; 38: 17-27.
41. Leyva F, Wingrove CS, Godsland IF, Stevenson JC. The glycolytic pathway to coronary heart disease: a hypothesis. Metabolism 1998; 47: 657-62.
42. Orynchak M, Neiko EM, Seredyuk VN. Insulin resistance and chronic heart failure. J Hypertens 2001; 19 (Suppl. 2): S284.
43. Reyes AJ. The increase in serum uric acid concentration caused by diuretics might be beneficial in heart failure. Eur J Heart Fail 2005; 7: 461-7.
44. McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312: 159-63.
45. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure. Validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107: 1991-7.
46. Sakai H, Tsutamoto T, Tsutsui T, Tanaka T, Ishikawa C, Horie M. Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure. Circ J 2006; 70: 1006-11.
47. Kojima S, Sakamoto T, Ishihara M, et al.; Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol 2005; 96: 489-95.
48. Ketai LH, Simon RH, Kreit JW, Grum CM. Plasma hypoxanthine and exercise. Am Rev Respir Dis 1987; 136: 98-101.
49. Issel EP, Lun A, Pohle R, Gross J. Hypoxanthine levels in amniotic fluid: an indicator of fetal hypoxia? J Perinat Med 1982; 10: 221-5.
50. Hasday JD, Grum CM. Nocturnal increase of urinary uric acid:creatinine ratio. A biochemical correlate of sleepassociated hypoxemia. Am Rev Respir Dis 1987; 135: 534-8.
51. Elsayed NM, Nakashima JM, Postlethwait EM. Measurement of uric acid as a marker of oxygen tension in the lung. Arch Biochem Biophys 1993; 302: 228-32.
52. Hayabuchi Y, Matsuoka S, Akita H, Kuroda Y. Hyperuricaemia in cyanotic congenital heart disease. Eur J Pediatr 1993; 152: 873-6.
53. Woolliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute illness: a poor prognostic sign. Am J Med 1982; 72: 58-62.
54. Huizer T, de Jong JW, Nelson JA, et al. Urate production by human heart. J Mol Cell Cardiol 1989; 21: 691-5.
55. Lazzarino G, Raatikainen P, Nuutinen M, et al. Myocardial release of malondialdehyde and purine compounds during coronary bypass surgery. Circulation 1994; 90: 291-7.
56. Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. Relationship between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 1997; 78: 39-43.
57. Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Relation between central and peripheral hemodynamics during exercise in patients with chronic heart failure. Circulation 1989; 80: 769-81.
58. Leyva F, Chua TP, Anker SD, Coats AJ. Uric acid in chronic heart failure: a measure of the anaerobic threshold. Metabolism 1998; 47: 1156-9.
59. Teng RJ, Ye YZ, Parks DA, Beckman JS. Urate produced during hypoxia protects heart proteins from peroxynitritemediated protein nitration. Free Radic Biol Med 2002; 33: 1243-9.
60. Trostchansky A, Ferrer-Sueta G, Batthyany C, et al. Peroxynitrite flux-mediated LDL oxidation is inhibited by manganese porphyrins in the presence of uric acid. Free Radic Biol Med 2003; 35: 1293-300.
61. Muraoka S, Miura T. Inhibition by uric acid of free radicals that damage biological molecules. Pharmacol Toxicol 2003; 93: 284-9.
62. Waring WS, Webb DJ, Maxwell SR. Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol 2001; 38: 365-71.
63. Bagnati M, Perugini C, Cau C, Bordone R, Albano E, Bellomo G. When and why a watersoluble antioxidant becomes pro-oxidant during copper induced low-density lipoprotein oxidation: a study using uric acid. Biochem J 1999; 340: 143-52.
64. Myers PR, Wright TF, Tanner MA, Ostlund RE Jr. The effects of native LDL and oxidized LDL on EDRF bioactivity and nitric oxide production in vascular endothelium. J Lab Clin Med 1994; 124: 672-83.
65. Drexler H, Hayoz D, Münzel T, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol 1992; 69: 1596-601.
66. Prasad K, Kalra J, Chan WP, Chaudhary AK. Effect of oxygen free radicals on cardiovascular function at organ and cellular levels. Am Heart J 1989; 117: 1196-202.
67. Belch JJ, Bridges AB, Scott N, Chopra M. Oxygen free radicals and congestive heart failure. Br Heart J 1991; 65: 245-8.
68. Cappola TP, Kass DA, Nelson GS, et al. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation 2001; 104: 2407-11.
69. Pérez NG, Gao WD, Marbán E. Novel myofilament calciumsensitizing property of xanthine oxidase inhibitors. Circ Res 1998; 83: 423-30.
70. Suga H. Ventricular energetics. Physiol Rev 1990; 70: 247-77.
71. Desco MC, Asensi M, Marquez R, et al. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 2002; 51: 1118-24.
72. Moorhouse PC, Grootveld M, Halliwell B, Quinlan JG, Gutteridge JM. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett 1987; 213: 23-8.
73. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart 2002; 87: 229-34.
74. Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. J Am Coll Cardiol 2001; 38: 1850-8.
75. Saavedra WF, Paolocci N, St John ME, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90: 297-304.
76. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystalindependent mechanism. Hypertension 2001; 38: 1101-06.
77. Barouch LA, Harrison RW, Skaf MW, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 2002; 416: 337-9.
78. Khan SA, Lee K, Minhas KM, et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 2004; 101: 15944-8.
79. Ukai T, Cheng CP, Tachibana H, et al. Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation 2001; 103: 750-5.
80. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown Pérez NG. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006; 12: 491-8.
81. Kögler H, Fraser H, McCune S, Altschuld R, Marbán Disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing myocardium. Cardiovasc Res 2003; 59: 582-92.
82. Kinugawa S, Tsutsui H, Hayashidani S, et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ Res 2000; 87: 392-8.
83. Engberding N, Spiekermann S, Schaefer A, et al. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 2004; 110: 2175-9.
84. Mellin V, Isabelle M, Oudot A, et al. Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure. Eur Heart J 2005; 26: 1544-50.
85. Stull LB, Leppo MK, Szweda L, Gao WD, Marban E. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 2004; 95: 1005-11.
86. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebocontrolled studies. Circulation 2002; 105: 2619-24.
87. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-6.
88. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-16.
89. Abraham WT, Fonarow GC, Albert NM, et al.; OPTIMIZE-HF Investigators and Coordinators. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008; 52: 347-56.
90. De Angelis S, Noce A, Di Renzo L, et al. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study. Eur Rev Med Pharmacol Sci 2007; 11: 179-84.